Does the media refer more to HYPD or VYGR?

In the previous week, Hyperion DeFi had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 5 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.43 beat Hyperion DeFi's score of 0.41 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is WHWK or HYPD more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Hyperion DeFi N/A -91.59% -73.08%

Does the media refer more to WHWK or HYPD?

In the previous week, Hyperion DeFi had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Hyperion DeFi's score of 0.41 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperion DeFi 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HYPD or FHTX?

In the previous week, Hyperion DeFi had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.62 beat Hyperion DeFi's score of 0.41 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGEN or HYPD?

In the previous week, Hyperion DeFi had 3 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat Hyperion DeFi's score of 0.41 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperion DeFi 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HYPD or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Nkarta N/A -30.90% -24.20%

Does the media favor HYPD or NKTX?

In the previous week, Hyperion DeFi had 4 more articles in the media than Nkarta. MarketBeat recorded 6 mentions for Hyperion DeFi and 2 mentions for Nkarta. Nkarta's average media sentiment score of 0.93 beat Hyperion DeFi's score of 0.41 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperion DeFi (HYPD) Competitors

$2.72 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.77 +0.05 (+1.76%)

As of 06/12/2026 07:59 PM Eastern

Compare

HYPD vs. VYGR, WHWK, FHTX, CGEN, and NKTX

Should you buy Hyperion DeFi stock or one of its competitors? MarketBeat compares Hyperion DeFi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperion DeFi include Voyager Therapeutics (VYGR), Whitehawk Therapeutics (WHWK), Foghorn Therapeutics (FHTX), Compugen (CGEN), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

How does Hyperion DeFi compare to Voyager Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Hyperion DeFi presently has a consensus price target of $5.65, indicating a potential upside of 107.72%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 371.43%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Hyperion DeFi had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 5 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.43 beat Hyperion DeFi's score of 0.41 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperion DeFi has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Hyperion DeFi has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Hyperion DeFi has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	50.91	-$45.31M	-$9.95	N/A
Voyager Therapeutics	$40.37M	5.24	-$119.72M	-$1.97	N/A

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Voyager Therapeutics beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Whitehawk Therapeutics' return on equity of -79.63% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Hyperion DeFi	N/A	-91.59%	-73.08%

Whitehawk Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 76.28%. Hyperion DeFi has a consensus price target of $5.65, suggesting a potential upside of 107.72%. Given Hyperion DeFi's higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Whitehawk Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Hyperion DeFi. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A
Hyperion DeFi	$810K	50.91	-$45.31M	-$9.95	N/A

In the previous week, Hyperion DeFi had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Hyperion DeFi's score of 0.41 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Whitehawk Therapeutics beats Hyperion DeFi on 9 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Foghorn Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Hyperion DeFi has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Hyperion DeFi has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	50.91	-$45.31M	-$9.95	N/A
Foghorn Therapeutics	$30.91M	7.94	-$74.28M	-$1.16	N/A

In the previous week, Hyperion DeFi had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.62 beat Hyperion DeFi's score of 0.41 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperion DeFi has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hyperion DeFi presently has a consensus target price of $5.65, indicating a potential upside of 107.72%. Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 173.41%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats Hyperion DeFi on 11 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Compugen?

Compugen (NASDAQ:CGEN) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 145.10%. Hyperion DeFi has a consensus price target of $5.65, indicating a potential upside of 107.72%. Given Compugen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Compugen is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Compugen has higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.65	$35.34M	$0.37	5.51
Hyperion DeFi	$810K	50.91	-$45.31M	-$9.95	N/A

Compugen has a net margin of 47.97% compared to Hyperion DeFi's net margin of 0.00%. Compugen's return on equity of 47.72% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Hyperion DeFi	N/A	-91.59%	-73.08%

Compugen has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

In the previous week, Hyperion DeFi had 3 more articles in the media than Compugen. MarketBeat recorded 6 mentions for Hyperion DeFi and 3 mentions for Compugen. Compugen's average media sentiment score of 0.62 beat Hyperion DeFi's score of 0.41 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compugen beats Hyperion DeFi on 13 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Nkarta?

Hyperion DeFi (NASDAQ:HYPD) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hyperion DeFi has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	50.91	-$45.31M	-$9.95	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Hyperion DeFi had 4 more articles in the media than Nkarta. MarketBeat recorded 6 mentions for Hyperion DeFi and 2 mentions for Nkarta. Nkarta's average media sentiment score of 0.93 beat Hyperion DeFi's score of 0.41 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperion DeFi has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Hyperion DeFi presently has a consensus price target of $5.65, suggesting a potential upside of 107.72%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 275.87%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nkarta's return on equity of -30.90% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Nkarta	N/A	-30.90%	-24.20%

Summary

Nkarta beats Hyperion DeFi on 9 of the 14 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPD vs. The Competition

Export

Metric	Hyperion DeFi	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.24M	$445.77M	$6.52B	$12.05B
Dividend Yield	N/A	3.88%	2.67%	5.66%
P/E Ratio	-0.27	3.18	24.00	24.42
Price / Sales	50.91	6,466.56	514.65	112.54
Price / Cash	N/A	13.13	27.48	37.92
Price / Book	0.58	89.46	10.69	6.82
Net Income	-$45.31M	-$96.07M	$3.57B	$337.56M
7 Day Performance	-7.17%	0.12%	0.61%	1.16%
1 Month Performance	-19.05%	-0.24%	1.56%	3.16%
1 Year Performance	11.48%	56.29%	25.44%	30.60%

Hyperion DeFi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPD Hyperion DeFi	4.1505 of 5 stars	$2.72 flat	$5.65 +107.7%	+11.5%	$41.24M	$810K	N/A	40
VYGR Voyager Therapeutics	3.4827 of 5 stars	$3.75 -3.2%	$16.50 +340.6%	+6.1%	$233.83M	$36.49M	N/A	100
WHWK Whitehawk Therapeutics	3.8893 of 5 stars	$4.21 -10.9%	$7.33 +74.4%	N/A	$233.42M	$7.14M	N/A	21
FHTX Foghorn Therapeutics	2.4749 of 5 stars	$3.77 -12.0%	$11.43 +203.5%	-3.2%	$233.39M	$28.22M	N/A	120	News Coverage Analyst Upgrade Gap Down
CGEN Compugen	3.9237 of 5 stars	$2.33 -11.6%	$5.00 +115.1%	+24.4%	$232.60M	$72.66M	6.42	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperion DeFi (HYPD) Competitors

HYPD vs. VYGR, WHWK, FHTX, CGEN, and NKTX

How does Hyperion DeFi compare to Voyager Therapeutics?

Summary

How does Hyperion DeFi compare to Whitehawk Therapeutics?

Summary

How does Hyperion DeFi compare to Foghorn Therapeutics?

Summary

How does Hyperion DeFi compare to Compugen?

Summary

How does Hyperion DeFi compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperion DeFi (HYPD) Competitors

HYPD vs. VYGR, WHWK, FHTX, CGEN, and NKTX

How does Hyperion DeFi compare to Voyager Therapeutics?

Do analysts recommend HYPD or VYGR?

Does the media refer more to HYPD or VYGR?

Is HYPD or VYGR more profitable?

Which has more volatility and risk, HYPD or VYGR?

Which has stronger earnings & valuation, HYPD or VYGR?

Do institutionals & insiders hold more shares of HYPD or VYGR?

Summary

How does Hyperion DeFi compare to Whitehawk Therapeutics?

Do institutionals and insiders have more ownership in WHWK or HYPD?

Is WHWK or HYPD more profitable?

Do analysts prefer WHWK or HYPD?

Which has more volatility & risk, WHWK or HYPD?

Which has higher valuation and earnings, WHWK or HYPD?

Does the media refer more to WHWK or HYPD?

Summary

How does Hyperion DeFi compare to Foghorn Therapeutics?

Is HYPD or FHTX more profitable?

Which has better earnings & valuation, HYPD or FHTX?

Does the media favor HYPD or FHTX?

Which has more risk and volatility, HYPD or FHTX?

Do institutionals & insiders believe in HYPD or FHTX?

Do analysts prefer HYPD or FHTX?

Summary

How does Hyperion DeFi compare to Compugen?

Do insiders & institutionals believe in CGEN or HYPD?

Do analysts recommend CGEN or HYPD?

Which has better earnings and valuation, CGEN or HYPD?

Is CGEN or HYPD more profitable?

Which has more risk & volatility, CGEN or HYPD?

Does the media refer more to CGEN or HYPD?

Summary

How does Hyperion DeFi compare to Nkarta?

Do insiders and institutionals have more ownership in HYPD or NKTX?

Which has better valuation & earnings, HYPD or NKTX?

Does the media favor HYPD or NKTX?

Which has more volatility and risk, HYPD or NKTX?

Do analysts recommend HYPD or NKTX?

Is HYPD or NKTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools